Macrophages Sequentially Change Their Functional Phenotype in Response to Changes in Microenvironmental Influences1

Recent studies have described the development of distinct functional subsets of macrophages in association with cancer, autoimmune disease, and chronic infections. Based on the ability of Th1 vs Th2 cytokines to promote opposing activities in macrophages, it has been proposed that macrophages develop into either type 1 inflammatory or type 2 anti-inflammatory subsets. As an alternative to the concept of subset development, we propose that macrophages, in response to changes in their tissue environment, can reversibly and progressively change the pattern of functions that they express. As demonstrated herein, macrophages can reversibly shift their functional phenotype through a multitude of patterns in response to changes in cytokine environment. Macrophages display distinct functional patterns after treatment with IFN-γ, IL-12, IL-4, or IL-10 and additional functional patterns are displayed depending on whether the cytokine is present alone or with other cytokines and whether the cytokines are added before or concomitantly with the activating stimulus (LPS). Sequential treatment of macrophages with multiple cytokines results in a progression through multiple functional phenotypes. This ability to adapt to changing cytokine environments has significant in vivo relevance, as evidenced by the demonstration that macrophage functional phenotypes established in vivo in aged or tumor-bearing mice can be altered by changing their microenvironment. A concept of functional adaptivity is proposed that has important implications for therapeutic targeting of macrophages in chronic diseases that result in the dominance of particular functional phenotypes of macrophages that play a significant role in disease pathology.

[1]  C. Rabourdin-Combe,et al.  Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. , 2004, Blood.

[2]  Li Wu,et al.  Are dendritic cells end cells? , 2004, Nature Immunology.

[3]  Hua Tang,et al.  Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells , 2004, Nature Immunology.

[4]  J. Suttles,et al.  Functional plasticity of macrophages: reversible adaptation to changing microenvironments , 2004, Journal of leukocyte biology.

[5]  T. Nomura,et al.  Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. , 2004, The Journal of clinical investigation.

[6]  G. Firestein The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. , 2004, The Journal of clinical investigation.

[7]  Timothy P Plackett,et al.  Aging and innate immune cells , 2004, Journal of leukocyte biology.

[8]  L. Steinman Immune Therapy for Autoimmune Diseases , 2004, Science.

[9]  F. Balkwill Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[10]  Marina Ziche,et al.  Development of new drugs in angiogenesis. , 2004, Current drug targets.

[11]  Lawrence Steinman,et al.  Elaborate interactions between the immune and nervous systems , 2004, Nature Immunology.

[12]  F. Brombacher,et al.  Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. , 2004, Immunity.

[13]  H. Neumann,et al.  Microglia: The Enemy Within? , 2003, Science.

[14]  L. Sibley,et al.  A novel population of Gr‐1+‐activated macrophages induced during acute toxoplasmosis , 2003, Journal of leukocyte biology.

[15]  M. Triggiani,et al.  The histamine-cytokine network in allergic inflammation. , 2003, The Journal of allergy and clinical immunology.

[16]  Piero Carninci,et al.  Genetic control of the innate immune response , 2003, BMC Immunology.

[17]  D. Mosser,et al.  The many faces of macrophage activation , 2003, Journal of leukocyte biology.

[18]  S. Bernstein,et al.  Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-γ1 , 2003, The Journal of Immunology.

[19]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  G. Laurent,et al.  Adhesion Molecule–dependent Mechanisms Regulate the Rate of Macrophage Clearance During the Resolution of Peritoneal Inflammation , 2002, The Journal of experimental medicine.

[21]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[22]  U. Hanisch,et al.  Microglia as a source and target of cytokines , 2002, Glia.

[23]  P. Finan,et al.  IL‐10 expression profiling in human monocytes , 2002, Journal of leukocyte biology.

[24]  Peter J. Murray,et al.  Shaping Gene Expression in Activated and Resting Primary Macrophages by IL-101 , 2002, The Journal of Immunology.

[25]  John Parkinson,et al.  IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype , 2002, BMC Immunology.

[26]  G. Chrousos,et al.  Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity , 2002, Annals of the New York Academy of Sciences.

[27]  David M. Mosser,et al.  Cutting Edge: Biasing Immune Responses by Directing Antigen to Macrophage Fcγ Receptors1 , 2002, The Journal of Immunology.

[28]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[29]  E. Pearce,et al.  Differential Regulation of Nitric Oxide Synthase-2 and Arginase-1 by Type 1/Type 2 Cytokines In Vivo: Granulomatous Pathology Is Shaped by the Pattern of l-Arginine Metabolism1 , 2001, The Journal of Immunology.

[30]  Kristi Kincaid,et al.  M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.

[31]  Constantin E. Orfanos,et al.  Alternative versus Classical Activation of Macrophages , 2000, Pathobiology.

[32]  D. Mullins,et al.  Tumor‐induced immune dysfunction: the macrophage connection , 1998, Journal of leukocyte biology.

[33]  S. Khoury,et al.  Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. , 1998, Journal of immunology.

[34]  M. Munder,et al.  Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. , 1998, Journal of immunology.

[35]  S. Goerdt,et al.  Differences in angiogenic potential of classically vs alternatively activated macrophages. , 1997, Immunobiology.

[36]  A. Meyerhans,et al.  Monocyte-derived dendritic cells represent a transient stage of differentiation in the myeloid lineage. , 1997, Immunobiology.

[37]  J. Suttles,et al.  T cell signaling of macrophage function in inflammatory disease. , 1997, Frontiers in bioscience : a journal and virtual library.

[38]  T. Olsson,et al.  Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β , 1995, Journal of Neuroimmunology.

[39]  J. Suttles,et al.  T-Cell Signaling of Macrophage Activation: Cell Contact-Dependent and Cytokine Signals , 1995 .

[40]  G. Trinchieri,et al.  Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production , 1995, The Journal of experimental medicine.

[41]  F. Herrmann,et al.  Discordant adaptation of human peritoneal macrophages to stimulation by lipopolysaccharide and the synthetic lipid A analogue SDZ MRL 953. Down-regulation of TNF-alpha and IL-6 is paralleled by an up-regulation of IL-1 beta and granulocyte colony-stimulating factor expression. , 1994, Journal of immunology.

[42]  C. Manthey,et al.  Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A , 1993, Infection and immunity.

[43]  S Gordon,et al.  Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation , 1992, The Journal of experimental medicine.

[44]  S. Gordon,et al.  Macrophages in tissues and in vitro. , 1992, Current opinion in immunology.

[45]  D. Adams,et al.  Gene Regulation in Macrophage Activation: Differential Regulation of Genes Encoding for Tumor Necrosis Factor, Interleukin‐1, JE, and KC by interferon‐γ and Lipopolysaccharide , 1990, Journal of leukocyte biology.

[46]  B. Brüne,et al.  PPAR γ – an Important Regulator of Monocyte / Macrophage Function , 2004 .

[47]  R. Diegelmann,et al.  Wound healing: an overview of acute, fibrotic and delayed healing. , 2004, Frontiers in bioscience : a journal and virtual library.

[48]  S. Gordon Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[49]  H. Neumann,et al.  Neuroscience. Microglia: the enemy within? , 2003, Science.

[50]  B. Brüne,et al.  PPARgamma--an important regulator of monocyte/macrophage function. , 2003, Archivum immunologiae et therapiae experimentalis.

[51]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[52]  H. Ziegler-Heitbrock,et al.  Interleukin-10 is upregulated in LPS tolerance. , 1995, Journal of inflammation.